710088Device for rapid point of care diagnosis of early stage lung cancerClosedGRD Proof of ConceptInnovate UKObjectives: To prove the feasibility of applying nanoparticle charge transfer technology (NCT) to the diagnososi of early stage lung cancer, by detecting and quantifying known chemical markers in controlled laboratory experiments. To design and build a portable prototype on-line device capable of detecting marker chemicals suitable for next phase POC clinical studies. Content: NCT is an innovative technology proprietary to Ancon Technologies Ltd, for the detection and analysis of airborne volatile and semivolatile chemicals (US Patent 7372020, GB2410091). NCT provides unprecedented levels of specificity and selectivity. It has been proven to detect semivolatile molecules in the air at appropriate concentrations to diagnose Tuberculosis NCT offers ground breaking sensitivity and selectivity and has been shown to detect semivolatile chemical compounds in concentrations as low as 1part in 10*18. This is 10*5 or 10*6 times more sensitive than the very best alternative technologies. NCT has the additional advantage of offering on-line results, with no waste products. The approach is non-invasive and accessible to patients. Devices are small, robust and portableideal for point of care diagnostics. There are 22 identified chemical markers for early satge lung cancer. The aim is to extend the functionality of the device developed for TB to make it suitable to detect such a wide range and large number of chemically similar molecules at very low concentrations. Deliverable: A robust prototype device able to detect the full range molecules which are known to be in the breath of patients with early stage lung cancer with sufficient selectivity and sensitivity to make it suitable for subsequent POC clinical studies